

# Alzheimer's Disease Neuroimaging Initiative

<https://neurodegenerationresearch.eu/cohort/alzheimer%20s-disease-neuroimaging-initiative/>

## Cohort Acronym

ADNI

## Cohort type

Neurodegenerative disease-specific cohort

## Disease

Alzheimer's disease, Mild cognitive impairment (MCI), Subjective memory complaints (SMC) or subjective cognitive decline (SCD)

## Participant type

Condition diagnosed

## Profile

Recruitment Period 2004

Sample size at start or planned sample size if still recruiting 1500

Estimated Current Sample Size 0 to 4,999

Age at Recruitment >55

Gender Male and Female

Abstract

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer's disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer's disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on [ADNI-info.org](http://ADNI-info.org). All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

- Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
- To detect Alzheimer's disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
- To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
- To continually develop ADNI's now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

*Last update – 07/02/2017*

Country Canada, USA

**Contact details**

Institution name Northern California Institute for Research and Education

Website <http://www.adni-info.org/Scientists/ADNIOverview.html>

Principal Investigator (PI) Michael W. Weiner MD

Contact email [michael.weiner@ucsf.edu](mailto:michael.weiner@ucsf.edu)

Contact phone number +11 31 415 750-2146

Funders (Core support) National Institute on Aging,

National Institute of Health,

Foundation for NIH (FNIH)

## Variables Collected

### **Brain related measures:**

Behaviour, Cognitive function, Mental health

### **Functional rating:**

Individual physiological, Individual psychological

### **Anthropometric:**

Blood pressure, Height, Weight

### **Physical:**

Hearing and Vision

### **Biological samples:**

Blood, Cerebral spinal fluid (CSF), CSF biomarker data available, Other, Urine

### **Genotyping:**

Gene screening

### **Brain imaging:**

Magnetic resonance imaging (MRI), Positron emission tomography (PET) - amyloid, Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)

### **Brain banking:**

Consent for brain donation

### **Lifestyle:**

Smoking

### **Socio-economic:**

Education, Ethnic group, Family circumstances, Marital status

### **Health service utilisation:**

N/A